The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
- PMID: 26845192
- DOI: 10.1016/j.jtho.2016.01.015
The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
Abstract
A malignant tumor is not merely an accumulation of neoplastic cells, but constitutes a microenvironment containing endothelial cells, fibroblasts, structural components, and infiltrating immune cells that impact tumor development, invasion, metastasis, and outcome. Hence, the evolution of cancers reflects intricate cellular and molecular interactions between tumor cells and constituents of the tumor microenvironment. Recent studies have shed new light on this complex interaction between tumor and host immune cells and the resulting immune response. The composition of the immune microenvironment differs across patients as well as in cancers of the same type, including various populations of T cells, B cells, dendritic cells, natural killer cells, myeloid-derived suppressor cells, neutrophils, and macrophages. The type, density, location, and organization of immune cells within solid tumors define the immune contexture, which has proved to be a major determinant of tumor characteristics and patient outcome. Lung cancer consists mostly of non-small cell lung cancer (85%); it is our most deadly malignant disease, with the 5-year survival rate being merely 15%. This review focuses on the immune contexture; the tumor-suppressing roles of tumor-infiltrating lymphocytes; and the relevance of this immune contexture for cancer diagnostics, prognostication, and treatment allocation, with an emphasis on non-small cell lung cancer.
Keywords: Immune context; Immunoscore; NSCLC; Prognosis; TILs; Tumor microenvironment.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Comment in
-
Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?J Thorac Oncol. 2016 Nov;11(11):e141-e142. doi: 10.1016/j.jtho.2016.07.029. J Thorac Oncol. 2016. PMID: 27770976 No abstract available.
Similar articles
-
Immune Cell Composition in Human Non-small Cell Lung Cancer.Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018. Front Immunol. 2019. PMID: 30774636 Free PMC article.
-
The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.J Thorac Oncol. 2011 Apr;6(4):824-33. doi: 10.1097/JTO.0b013e3182037b76. J Thorac Oncol. 2011. PMID: 21173711 Review.
-
Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC. Am J Respir Crit Care Med. 2018. PMID: 29518341
-
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90. doi: 10.1164/rccm.201409-1671PP. Am J Respir Crit Care Med. 2015. PMID: 25369536 Free PMC article. Review.
-
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.Int J Cancer. 2017 Feb 15;140(4):888-899. doi: 10.1002/ijc.30489. Epub 2016 Nov 7. Int J Cancer. 2017. PMID: 27785783
Cited by
-
Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy.Oncol Lett. 2020 Jul;20(1):517-524. doi: 10.3892/ol.2020.11605. Epub 2020 May 13. Oncol Lett. 2020. PMID: 32565977 Free PMC article.
-
The Role of the ECM in Lung Cancer Dormancy and Outgrowth.Front Oncol. 2020 Sep 11;10:1766. doi: 10.3389/fonc.2020.01766. eCollection 2020. Front Oncol. 2020. PMID: 33014869 Free PMC article. Review.
-
Dysregulation of the DRAIC/SBK1 Axis Promotes Lung Cancer Progression.Diagnostics (Basel). 2024 Oct 5;14(19):2227. doi: 10.3390/diagnostics14192227. Diagnostics (Basel). 2024. PMID: 39410631 Free PMC article.
-
Ninety-six-hour starved peripheral blood mononuclear cell supernatant inhibited LA7 breast cancer stem cells induced tumor via reduction in angiogenesis and alternations in Gch1 and Spr expressions.Front Immunol. 2023 Feb 23;13:1025933. doi: 10.3389/fimmu.2022.1025933. eCollection 2022. Front Immunol. 2023. PMID: 36908807 Free PMC article.
-
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.Front Immunol. 2023 Mar 7;14:1090533. doi: 10.3389/fimmu.2023.1090533. eCollection 2023. Front Immunol. 2023. PMID: 36960052 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical